A phase 1b/11 , multicenter , open label study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma.
(In Utrecht gesloten voor inclusie)
Lee011 and MEK162
Stadium irresectable IIIc/IV
In: ECOG performance status of 0-2, phase 1b enrolled patients may have evaluable disease only; phase 2 enrolled patients must have a least one measurable lesion as defined by RECIST 1.1 criteria. Ex: symptomatic brain metastases, impaired cardiac function, receiving treatment that is metabolized through CYP2A4, treatment with agents that are known to cause QTc prologation, retinal disease.